Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
With a mission to support novel approaches to managing and preventing heart failure, the Ted Rogers Centre for Heart Research uses its Innovation Fund to propel emerging research with great potential. In our 2024-25 Innovation Seed Grant competition, the Centre funded...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Engineering of human tissue, with a focus on the heart, is a main research topic of the Zimmermann lab. The seminar will touch upon different models of in vitro organogenesis with applications in disease modelling, drug development, and tissue engineered heart repair. Mechanisms underlying self-organization of pluripotent stem cell-derived cardiomyocytes into functional myocardium will be discussed. Examples for the application of Engineered Human Myocardium (EHM) in the preclinical development of therapeutic genome editing in patients with Duchenne Muscular Dystrophy and the translation of tissue engineered heart failure repair into clinical applications will be presented.